Dynamics of SARS-CoV-2 exposure in Malawian blood donors: a retrospective seroprevalence analysis between January 2020 and February 2021

Abstract

BackgroundAs at end of July 2021, the COVID-19 pandemic has been less severe in sub-Saharan Africa than elsewhere. In Malawi, there have been two subsequent epidemic waves. We therefore aimed to describe the dynamics of SARS-CoV-2 exposure in Malawi.MethodsWe measured the seroprevalence of anti-SARS-CoV-2 antibodies among randomly selected blood donor sera in Malawi from January 2020 to February 2021. In a subset, we also assesed in vitro neutralisation against the original variant (D614G WT) and the Beta variant.FindingsA total of 3586 samples were selected from the blood donor database, of which 2685 (74.9%) were male and 3132 (87.3%) were aged 20-49 years. Of the total, 469 (13.1%) were seropositive. Seropositivity was highest in October 2020 (15.7%) and February 2021 (49.7%) reflecting the two epidemic waves. Unlike the first wave, both urban and rural areas had high seropositivity by February 2021, Balaka (rural, 37.5%), Blantyre (urban, 54.8%), Lilongwe (urban, 54.5%) and Mzuzu (urban, 57.5%). First wave sera showed potent in vitro neutralisation activity against the original variant (78%[7/9]) but not the Beta variant (22% [2/9]). Second wave sera potently neutralised the Beta variant (73% [8/11]).InterpretationThe findings confirm extensive SARS-CoV-2 exposure in Malawi over two epidemic waves with likely poor cross-protection to reinfection from the first on the second wave. Since prior exposure augments COVID-19 vaccine immunity, prioritising administration of the first dose in high SARS-CoV-2 exposure settings could maximise the benefit of the limited available vaccines in Malawi and the region.Research in contextEvidence before this studyWe searched PubMed on August 16, 2021, with no language restrictions, for titles and abstracts published between Jan 1, 2020, and August 16, 2021, using the search terms: “SARS-CoV-2 seroprevalence in Africa”[Title/Abstract]) OR “SARS-CoV-2 seroprevalence in blood donors” [Title/Abstract] OR “SARS-CoV-2 seroprevalence in Malawi”, and found 15 records. There are limited SARS-CoV-2 seroprevalence studies in sub Saharan Africa, however the few that are available report high seroprevalence than can be deduced from the respective national reported COVID-19 cases and deaths. Only two published SARS-CoV-2 serosurveys were done on blood donors, from Kenya and Madagascar. Blood donor serosurveys have been recommended by the WHO as an important tool for assessing the spread of SARS-CoV-2 and estimating the burden of COVID-19 pandemic.Added value of this studyUnlike previous SARS-CoV-2 blood donor serosurveys in African populations that were conducted for a maximum period of 9 months, our study covers a full year from January 2020 to February 2021, capturing potential introduction of SARS-CoV-2 into Malawi as well as the two epidemic waves. This study provides evidence against the speculation that SARS-CoV-2 had been circulating more widely in sub-Saharan Africa before the first detected cases. It also provides supporting evidence suggesting that the Beta variant was the likely driver of the second wave that resulted in high SARS-CoV-2 seropositivity in January to February 2021 in Malawi.Implications of all the available evidenceOur results show extensive community transmission of SARS-CoV-2 in Malawi as reflected in the blood donors serosurvey, with almost half the sample population being seropositive for anti-SARS-CoV-2 antibodies by February 2021. This has implications for COVID-19 vaccination policy in sub-Saharan Africa (SSA), where there are limited available vaccine doses. Considering that prior exposure to SARS-CoV-2 augments COVID-19 vaccine immunity, strategies to maximise administration of the first vaccine dose, while waiting for more vaccines to become available, could maximise the benefits of the limited available vaccines in high SARS-CoV-2 exposure settings in SSA such as Malawi.

Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa

“…The copyright holder for this this version posted December 21, 2021. ; https://doi.org/10.1101/2021.12. 19.21268028 doi: medRxiv preprint the Delta wave suggested high levels of exposure to SARS-CoV-2 (40-60%) in South Africa 11,12 , Malawi 13 , and Zimbabwe 14 , and modelled estimates suggested seroprevalence of 70-80% across South Africa by October 2021 15 . Accordingly, the weeks following the third wave in South Africa, between 10 October and 15 November 2021, were marked by a period of lower-level transmission as indicated by a low incidence of reported COVID-19 cases (100-200 new cases per day) and low (<2%) test positivity rates (Fig.…”

The impact of COVID-19 on pregnant and recently pregnant women in Malawi: A national facility-based cohort

“…For example, early in the pandemic, the national lockdown in Nepal was associated with an increase in the institutional stillbirth rate and neonatal mortality, and a decrease in the quality of care (10). Malawi had registered 62,088 confirmed COVID-19 cases, 2,307 COVID-19 related deaths and 58,846 recoveries as of evidence of prior infection in February,2021, which is now reported to be as high as 80% in the city of Blantyre (southern region) (12). The pandemic has challenged the country's healthcare system, resulting in a disruption in the delivery of quality healthcare (13).…”

“…Malawi had registered 62,088 confirmed COVID-19 cases, 2,307 COVID-19 related deaths and 58,846 recoveries as of 10 th December 2021 (11). These absolute numbers of reported cases may also reflect limited testing capacity and uptake, as sero-surveillance has demonstrated that 51.1% of the population had serological evidence of prior infection in February,2021, which is now reported to be as high as 80% in the city of Blantyre (southern region) (12). The pandemic has challenged the country's healthcare system, resulting in a disruption in the delivery of quality healthcare (13).…”